Hoffmann-La Roche Inc. (RHHBY) Release: New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
1/16/2009 10:33:02 AM
More...
|
What Happens When a Biotech Gets Bought Out
9/9/2008 7:53:48 AM
More...
|
Hoffmann-La Roche Inc. (RHHBY) Release: CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI
6/4/2008 12:35:35 PM
More...
|
Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
5/22/2008 10:41:41 AM
More...
|
Hoffmann-La Roche Inc. (RHHBY) Achieves EPA Climate Leaders Goal Two Years Ahead of Schedule
12/5/2007 2:56:16 PM
More...
|
Hepatitis C Treatment Reduces the Virus but Serious Liver Problems May Progress
11/7/2007 12:37:40 AM
More...
|
Roche (RHHBY): Final Gemini Study Results Confirm Boosted Invirase Was as Effective as Kaletra While Providing an Improved Triglyceride Profile for HIV Patients
10/25/2007 8:50:51 AM
More...
|
Hoffmann-La Roche Inc. (RHHBY) Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
10/23/2007 11:24:46 AM
More...
|
Hoffmann-La Roche Inc. (RHHBY) New Data Suggest Boosted Invirase(R) has Similar Efficacy to Boosted Lopinavir in HIV Patients at 24 Weeks
7/23/2007 8:23:48 AM
More...
|
Hoffmann-La Roche Inc. (RHHBY): Data Suggest that PEGASYS(R) May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron(R)
5/21/2007 1:32:01 PM
More...
|
|